Introduktion
Denne side giver en omfattende analyse af den kendte insiderhandelshistorie for Kevin Kotler. Insidere er embedsmænd, direktører eller betydelige investorer i en virksomhed. Det er ulovligt for insidere at foretage handler i deres virksomheder baseret på specifik, ikke-offentlig information. Dette betyder ikke, at det er ulovligt for dem at handle i deres egne virksomheder. De skal dog rapportere alle handler til SEC via en formular 4. På trods af disse begrænsninger tyder akademisk forskning på, at insidere - generelt - har en tendens til at klare sig bedre end markedet i deres egne virksomheder.
Gennemsnitlig handelsrentabilitet
Den gennemsnitlige handelsrentabilitet er det gennemsnitlige afkast af alle køb på det åbne marked foretaget af insideren i de sidste tre år. For at beregne dette undersøger vi ethvert åbent marked, uplanlagte køb foretaget af insideren, eksklusive alle handler, der var markeret som en del af en 10b5-1-handelsplan. Vi beregner derefter den gennemsnitlige præstation for disse handler over 3, 6 og 12 måneder, idet vi tager et gennemsnit af hver af disse varigheder for at generere en endelig præstationsmåling for hver handel. Endelig tager vi et gennemsnit af alle præstationsmålingerne for at beregne en præstationsmåling for insideren. Denne liste inkluderer kun insidere, der har foretaget mindst tre handler i de sidste to år.
Hvis denne insiderhandelsrentabilitet er "N/A", så har insideren enten ikke foretaget nogen køb på det åbne marked i de sidste tre år, eller de handler, de har foretaget, er for nye til at beregne en pålidelig præstationsmåling.
Opdateringsfrekvens: Dagligt
Virksomheder med rapporterede insider-stillinger
SEC-registreringen viser, at Kevin Kotler har rapporteret besiddelser eller handler i følgende virksomheder:
Sikkerhed | Titel | Senest indberettede beholdninger |
---|---|---|
US:HRTX / Heron Therapeutics, Inc. | Director | 37.879 |
US:BDSI / Biodelivery Sciences International | Director | 0 |
US:NVLNF / Novelion Therapeutics Inc. | 10% Owner | 5.082.444 |
US:AVDL / Avadel Pharmaceuticals plc | Director | 60.000 |
US:PETX / Aratana Therapeutics, Inc. | 10% Owner | 0 |
US:CORI / Corium International, Inc. | 10% Owner | 0 |
US:REPH / Societal CDMO Inc | 10% Owner | 2.048.025 |
US:MRTX / Mirati Therapeutics, Inc. | 10% Owner | 2.728.601 |
US:PGNX / Progenics Pharmaceuticals, Inc. | 10% Owner | 6.997.269 |
US:AEGR / Aegerion Pharmaceuticals, Inc. | 10% Owner | 0 |
US:SSKN / STRATA Skin Sciences, Inc. | 10% Owner | 1.008.297 |
US:CRDC / Cardica, Inc. | 10% Owner | 17.749.984 |
US:TVTX / Travere Therapeutics, Inc. | 10% Owner | 5.317.708 |
Sådan fortolkes diagrammerne
Følgende diagrammer viser aktieudviklingen for værdipapirer efter hver åben-marked, ikke-planlagt handel foretaget af Kevin Kotler. Ikke-planlagt handel er handler, der ikke blev foretaget som en del af en 10b5-1-handelsplan. Aktieudviklingen er kortlagt som den kumulative procentvise ændring i aktiekursen. For eksempel, hvis en insiderhandel blev foretaget den 1. januar 2019, vil diagrammet vise den daglige procentvise ændring af værdipapiret til i dag. Hvis aktiekursen skulle gå fra $10 til $15 i løbet af denne tid, ville den kumulative procentvise ændring i aktiekursen være 50%. En prisændring fra 10 USD til 20 USD ville være 100 %, og en ændring i prisen på 10 USD til 5 USD ville være -50 %.
I sidste ende forsøger vi at bestemme, hvor tæt insiderens handler korrelerer med merafkast (positive eller negative) i aktiekursen for at se, om insideren timing deres handler til at drage fordel af insiderinformation. Overvej situationen, hvor en insider gjorde dette. I denne situation ville vi forvente enten (a) positive afkast efter køb eller (b) negative afkast efter salg. I tilfælde af (a) vil KØB-diagrammet vise en række opadskrånende kurver, der indikerer positive afkast efter hver købstransaktion. I tilfælde af (b) vil SALE-diagrammet vise en række nedadgående kurver, der indikerer negative afkast efter hver salgstransaktion.
Dette alene er dog ikke nok til at drage konklusioner. Hvis for eksempel aktiekursen i selskabet var i en ikke-cyklisk stigning over mange år, så ville vi forvente, at alle efterkøbsgrundene var opadgående. Ligeledes ville ikke-cykliske fald over mange år resultere i nedadgående post-trade plots. Ingen af disse diagrammer tyder på insiderhandel.
Den stærkeste indikator ville være en situation, hvor aktiekursen var ekstremt cyklisk, og der var både positive signaler i KØB-diagrammet og negative plots på SALG-diagrammet. Denne situation ville i høj grad tyde på en insider, der havde timing af handler til deres økonomiske fordel.
Insiderkøb AVDL / Avadel Pharmaceuticals plc – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i AVDL / Avadel Pharmaceuticals plc. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Maks |
Pris kl Maks |
Maks Fortjeneste ($) |
Maks. afkast (%) |
---|---|---|---|---|---|---|---|
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg AVDL / Avadel Pharmaceuticals plc – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i AVDL / Avadel Pharmaceuticals plc. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderkøb HRTX / Heron Therapeutics, Inc. – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i AVDL / Avadel Pharmaceuticals plc. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Maks |
Pris kl Maks |
Maks Fortjeneste ($) |
Maks. afkast (%) |
---|---|---|---|---|---|---|---|
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg HRTX / Heron Therapeutics, Inc. – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i AVDL / Avadel Pharmaceuticals plc. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Min |
Pris kl Min |
Max tab Undgået ($) |
Max tab Undgået (%) |
---|---|---|---|---|---|---|---|
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderkøb QLTI / The 2023 ETF Series Trust II - GMO International Quality ETF – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i AVDL / Avadel Pharmaceuticals plc. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Maks |
Pris kl Maks |
Maks Fortjeneste ($) |
Maks. afkast (%) |
---|---|---|---|---|---|---|---|
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg QLTI / The 2023 ETF Series Trust II - GMO International Quality ETF – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i AVDL / Avadel Pharmaceuticals plc. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderkøb SSKN / STRATA Skin Sciences, Inc. – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i AVDL / Avadel Pharmaceuticals plc. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Maks |
Pris kl Maks |
Maks Fortjeneste ($) |
Maks. afkast (%) |
---|---|---|---|---|---|---|---|
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg SSKN / STRATA Skin Sciences, Inc. – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i AVDL / Avadel Pharmaceuticals plc. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderkøb TVTX / Travere Therapeutics, Inc. – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i AVDL / Avadel Pharmaceuticals plc. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Maks |
Pris kl Maks |
Maks Fortjeneste ($) |
Maks. afkast (%) |
---|---|---|---|---|---|---|---|
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg TVTX / Travere Therapeutics, Inc. – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i AVDL / Avadel Pharmaceuticals plc. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Min |
Pris kl Min |
Max tab Undgået ($) |
Max tab Undgået (%) |
---|---|---|---|---|---|---|---|
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderhandelshistorie
Denne tabel viser den komplette liste over insiderhandler foretaget af Kevin Kotler som oplyst til Securities Exchange Commission (SEC).
Fil dato | Transdato | Form | Ticker | Sikkerhed | Kode | Aktier | Resterende aktier | Procent Lave om |
Del Pris |
Tran Værdi |
Tilbage Værdi |
|
---|---|---|---|---|---|---|---|---|---|---|---|---|
2023-03-02 | 3 | HRTX |
HERON THERAPEUTICS, INC. /DE/
Common Stock |
37.879 | ||||||||
2023-03-02 | 3 | HRTX |
HERON THERAPEUTICS, INC. /DE/
Common Stock |
540.000 | ||||||||
2022-03-22 |
|
4 | BDSI |
BIODELIVERY SCIENCES INTERNATIONAL INC
Stock Options (right to buy) |
D - Sale to Issuer | -85.760 | 0 | -100,00 | ||||
2022-03-22 |
|
4 | BDSI |
BIODELIVERY SCIENCES INTERNATIONAL INC
Stock Options (right to buy) |
D - Sale to Issuer | -7.500 | 0 | -100,00 | ||||
2022-03-22 |
|
4 | BDSI |
BIODELIVERY SCIENCES INTERNATIONAL INC
Restricted Stock Units |
D - Sale to Issuer | -22.685 | 0 | -100,00 | ||||
2022-03-22 |
|
4 | BDSI |
BIODELIVERY SCIENCES INTERNATIONAL INC
Common Stock |
J - Other | -7.588.395 | 0 | -100,00 | ||||
2022-02-15 |
|
4 | BDSI |
BIODELIVERY SCIENCES INTERNATIONAL INC
Series B Convertible Preferred Stock |
C - Conversion | -436 | 0 | -100,00 | 10.000,00 | -4.360.000 | ||
2022-02-15 |
|
4 | BDSI |
BIODELIVERY SCIENCES INTERNATIONAL INC
Common Stock |
C - Conversion | 2.422.222 | 7.588.395 | 46,89 | 1,80 | 4.360.000 | 13.659.111 | |
2022-01-31 |
|
4 | BDSI |
BIODELIVERY SCIENCES INTERNATIONAL INC
Restricted Stock Units |
M - Exercise | -7.684 | 7.685 | -50,00 | ||||
2022-01-31 |
|
4 | BDSI |
BIODELIVERY SCIENCES INTERNATIONAL INC
Restricted Stock Units |
A - Award | 15.369 | 15.369 | |||||
2022-01-31 |
|
4 | BDSI |
BIODELIVERY SCIENCES INTERNATIONAL INC
Stock Options (right to buy) |
A - Award | 85.760 | 85.760 | |||||
2022-01-31 |
|
4 | BDSI |
BIODELIVERY SCIENCES INTERNATIONAL INC
Common Stock |
M - Exercise | 7.684 | 5.166.173 | 0,15 | ||||
2021-11-22 |
|
4 | BDSI |
BIODELIVERY SCIENCES INTERNATIONAL INC
Common Stock |
P - Purchase | 100.000 | 5.158.489 | 1,98 | 3,06 | 306.000 | 15.784.976 | |
2021-11-15 |
|
4 | BDSI |
BIODELIVERY SCIENCES INTERNATIONAL INC
Common Stock |
P - Purchase | 100.000 | 5.058.489 | 2,02 | 3,20 | 320.000 | 16.187.165 | |
2021-11-09 |
|
4 | BDSI |
BIODELIVERY SCIENCES INTERNATIONAL INC
Common Stock |
P - Purchase | 257.800 | 4.958.489 | 5,48 | 3,47 | 894.566 | 17.205.957 | |
2021-08-10 |
|
4 | BDSI |
BIODELIVERY SCIENCES INTERNATIONAL INC
Stock Options (right to buy) |
C - Conversion | 15.000 | 7.500 | -200,00 | 2,93 | 43.950 | 21.975 | |
2021-08-10 |
|
4 | BDSI |
BIODELIVERY SCIENCES INTERNATIONAL INC
Common Stock |
M - Exercise | 15.000 | 4.700.689 | 0,32 | 2,93 | 43.950 | 13.773.019 | |
2021-08-10 |
|
4 | BDSI |
BIODELIVERY SCIENCES INTERNATIONAL INC
Restricted Stock Units |
M - Exercise | -30.000 | 15.000 | -66,67 | ||||
2021-08-10 |
|
4 | BDSI |
BIODELIVERY SCIENCES INTERNATIONAL INC
Common Stock |
M - Exercise | 30.000 | 4.685.689 | 0,64 | ||||
2021-05-13 |
|
4 | BDSI |
BIODELIVERY SCIENCES INTERNATIONAL INC
Common Stock |
P - Purchase | 50.000 | 4.655.689 | 1,09 | 3,25 | 162.500 | 15.130.989 | |
2021-05-13 |
|
4 | BDSI |
BIODELIVERY SCIENCES INTERNATIONAL INC
Common Stock |
P - Purchase | 100.000 | 4.605.689 | 2,22 | 3,24 | 324.000 | 14.922.432 | |
2021-05-13 |
|
4 | BDSI |
BIODELIVERY SCIENCES INTERNATIONAL INC
Common Stock |
P - Purchase | 150.000 | 4.505.689 | 3,44 | 3,16 | 474.000 | 14.237.977 | |
2020-08-11 |
|
4 | BDSI |
BIODELIVERY SCIENCES INTERNATIONAL INC
Stock Options (right to buy) |
C - Conversion | 15.000 | 22.500 | 200,00 | ||||
2020-08-11 |
|
4 | BDSI |
BIODELIVERY SCIENCES INTERNATIONAL INC
Restricted Stock Units |
M - Exercise | -30.000 | 45.000 | -40,00 | ||||
2020-08-11 |
|
4 | BDSI |
BIODELIVERY SCIENCES INTERNATIONAL INC
Common Stock |
M - Exercise | 15.000 | 4.355.689 | 0,35 | 2,93 | 43.950 | 12.762.169 | |
2020-08-11 |
|
4 | BDSI |
BIODELIVERY SCIENCES INTERNATIONAL INC
Common Stock |
M - Exercise | 30.000 | 4.340.689 | 0,70 | ||||
2020-03-19 |
|
4 | BDSI |
BIODELIVERY SCIENCES INTERNATIONAL INC
Options |
C - Conversion | -10.623 | 37.500 | -22,07 | ||||
2020-03-19 |
|
4 | BDSI |
BIODELIVERY SCIENCES INTERNATIONAL INC
Common Stock |
M - Exercise | -10.623 | 4.310.689 | -0,25 | 2,93 | -31.125 | 12.630.319 | |
2020-01-15 | 3 | NVLNF |
NOVELION THERAPEUTICS INC.
Common Shares |
5.082.444 | ||||||||
2020-01-15 | 3 | NVLNF |
NOVELION THERAPEUTICS INC.
Common Shares |
5.082.444 | ||||||||
2020-01-15 | 3 | NVLNF |
NOVELION THERAPEUTICS INC.
Common Shares |
5.082.444 | ||||||||
2020-01-15 | 3 | NVLNF |
NOVELION THERAPEUTICS INC.
Common Shares |
5.082.444 | ||||||||
2020-01-15 | 3 | NVLNF |
NOVELION THERAPEUTICS INC.
Common Shares |
5.082.444 | ||||||||
2019-12-20 |
|
4 | BDSI |
BIODELIVERY SCIENCES INTERNATIONAL INC
Series B Convertible Preferred Stock |
C - Conversion | -360 | 436 | -45,23 | 10.000,00 | -3.600.000 | 4.360.000 | |
2019-12-20 |
|
4 | BDSI |
BIODELIVERY SCIENCES INTERNATIONAL INC
Common Stock |
C - Conversion | 2.000.000 | 4.300.066 | 86,95 | 1,80 | 3.600.000 | 7.740.119 | |
2019-12-20 |
|
4 | BDSI |
BIODELIVERY SCIENCES INTERNATIONAL INC
Common Stock |
S - Sale | -1.000.000 | 2.300.066 | -30,30 | 6,32 | -6.320.000 | 14.536.417 | |
2019-12-20 |
|
4 | BDSI |
BIODELIVERY SCIENCES INTERNATIONAL INC
Common Stock |
S - Sale | -750.000 | 3.300.066 | -18,52 | 6,50 | -4.875.000 | 21.450.429 | |
2019-12-20 |
|
4 | BDSI |
BIODELIVERY SCIENCES INTERNATIONAL INC
Common Stock |
S - Sale | -250.000 | 4.050.066 | -5,81 | 6,44 | -1.610.000 | 26.082.425 | |
2019-11-19 |
|
4 | BDSI |
BIODELIVERY SCIENCES INTERNATIONAL INC
Series B Convertible Preferred Stock |
C - Conversion | -720 | 796 | -47,49 | 10.000,00 | -7.200.000 | 7.960.000 | |
2019-11-19 |
|
4 | BDSI |
BIODELIVERY SCIENCES INTERNATIONAL INC
Common Stock |
C - Conversion | 4.000.000 | 4.300.066 | 1.333,04 | 1,80 | 7.200.000 | 7.740.119 | |
2019-11-19 |
|
4 | BDSI |
BIODELIVERY SCIENCES INTERNATIONAL INC
Common Stock |
S - Sale | -1.500.000 | 300.066 | -83,33 | 5,90 | -8.850.000 | 1.770.389 | |
2019-11-19 |
|
4 | BDSI |
BIODELIVERY SCIENCES INTERNATIONAL INC
Common Stock |
S - Sale | -293.757 | 1.800.066 | -14,03 | 5,90 | -1.734.165 | 10.626.510 | |
2019-11-19 |
|
4 | BDSI |
BIODELIVERY SCIENCES INTERNATIONAL INC
Common Stock |
S - Sale | -2.206.243 | 2.093.823 | -51,31 | 6,04 | -13.319.089 | 12.640.409 | |
2019-08-15 |
|
4 | BDSI |
BIODELIVERY SCIENCES INTERNATIONAL INC
Restricted Stock Units |
M - Exercise | -18.123 | 75.000 | -19,46 | ||||
2019-08-15 |
|
4 | BDSI |
BIODELIVERY SCIENCES INTERNATIONAL INC
Common Stock |
M - Exercise | 18.123 | 4.300.066 | 0,42 | ||||
2019-08-09 |
|
4 | AVDL |
AVADEL PHARMACEUTICALS PLC
Stock Option (right to buy) |
A - Award | 60.000 | 60.000 | |||||
2019-07-22 |
|
4 | PETX |
ARATANA THERAPEUTICS, INC.
Common Stock |
D - Sale to Issuer | -7.258.135 | 0 | -100,00 | ||||
2019-05-14 |
|
4 | BDSI |
BIODELIVERY SCIENCES INTERNATIONAL INC
Series B Convertible Preferred Stock |
C - Conversion | 324 | 1.516 | 27,18 | 10.000,00 | 3.240.000 | 15.160.000 | |
2019-05-14 |
|
4 | BDSI |
BIODELIVERY SCIENCES INTERNATIONAL INC
Common Stock |
S - Sale | -1.800.000 | 4.281.943 | -29,60 | 5,00 | -9.000.000 | 21.409.715 | |
2019-04-15 |
|
4 | BDSI |
BIODELIVERY SCIENCES INTERNATIONAL INC
Series B Convertible Preferred Stock |
C - Conversion | 360 | 1.840 | 24,32 | 10.000,00 | 3.600.000 | 18.400.000 | |
2019-04-15 |
|
4 | BDSI |
BIODELIVERY SCIENCES INTERNATIONAL INC
Common Stock |
S - Sale | -2.000.000 | 4.281.943 | -31,84 | 5,00 | -10.000.000 | 21.409.715 | |
2019-02-04 |
|
4 | AVDL |
AVADEL PHARMACEUTICALS PLC
ADSs |
A - Award | 27.900 | 3.130.573 | 0,90 | ||||
2019-01-22 | 3 | PETX |
ARATANA THERAPEUTICS, INC.
Common Stock |
14.516.270 | ||||||||
2019-01-22 | 3 | PETX |
ARATANA THERAPEUTICS, INC.
Common Stock |
14.516.270 | ||||||||
2019-01-22 | 3 | PETX |
ARATANA THERAPEUTICS, INC.
Common Stock |
14.516.270 | ||||||||
2019-01-22 | 3 | PETX |
ARATANA THERAPEUTICS, INC.
Common Stock |
14.516.270 | ||||||||
2019-01-22 | 3 | PETX |
ARATANA THERAPEUTICS, INC.
Common Stock |
14.516.270 | ||||||||
2018-12-27 |
|
4 | NVLN |
NOVELION THERAPEUTICS INC.
Common Shares, without par value |
S - Sale | -100.000 | 1.498.553 | -6,26 | 0,85 | -85.140 | 1.275.868 | |
2018-12-27 |
|
4 | NVLN |
NOVELION THERAPEUTICS INC.
Common Shares, without par value |
S - Sale | -56.316 | 1.598.553 | -3,40 | 0,85 | -48.139 | 1.366.443 | |
2018-12-27 |
|
4 | NVLN |
NOVELION THERAPEUTICS INC.
Common Shares, without par value |
S - Sale | -14.800 | 1.654.869 | -0,89 | 0,88 | -13.028 | 1.456.781 | |
2018-12-27 |
|
4 | NVLN |
NOVELION THERAPEUTICS INC.
Common Shares, without par value |
S - Sale | -30.726 | 1.669.669 | -1,81 | 0,91 | -27.868 | 1.514.390 | |
2018-12-27 |
|
4 | NVLN |
NOVELION THERAPEUTICS INC.
Common Shares, without par value |
S - Sale | -28.745 | 1.700.395 | -1,66 | 0,91 | -26.037 | 1.540.218 | |
2018-12-27 |
|
4 | NVLN |
NOVELION THERAPEUTICS INC.
Common Shares, without par value |
S - Sale | -12.219 | 1.729.140 | -0,70 | 0,91 | -11.108 | 1.571.961 | |
2018-12-27 |
|
4 | NVLN |
NOVELION THERAPEUTICS INC.
Common Shares, without par value |
S - Sale | -109.900 | 1.741.359 | -5,94 | 0,87 | -95.833 | 1.518.465 | |
2018-12-27 |
|
4 | NVLN |
NOVELION THERAPEUTICS INC.
Common Shares, without par value |
S - Sale | -12.450 | 1.851.259 | -0,67 | 0,91 | -11.302 | 1.680.573 | |
2018-12-27 |
|
4 | NVLN |
NOVELION THERAPEUTICS INC.
Common Shares, without par value |
S - Sale | -83.245 | 1.863.709 | -4,28 | 0,98 | -81.447 | 1.823.453 | |
2018-12-27 |
|
4 | NVLN |
NOVELION THERAPEUTICS INC.
Common Shares, without par value |
S - Sale | -1.200 | 1.946.954 | -0,06 | 0,93 | -1.119 | 1.815.535 | |
2018-12-27 |
|
4 | NVLN |
NOVELION THERAPEUTICS INC.
Common Shares, without par value |
S - Sale | -400 | 1.948.154 | -0,02 | 0,98 | -392 | 1.909.191 | |
2018-12-13 | 3 | AVDL |
AVADEL PHARMACEUTICALS PLC
ADSs |
6.205.346 | ||||||||
2018-12-13 | 3 | AVDL |
AVADEL PHARMACEUTICALS PLC
ADSs |
6.205.346 | ||||||||
2018-12-13 | 3 | AVDL |
AVADEL PHARMACEUTICALS PLC
ADSs |
6.205.346 | ||||||||
2018-12-13 | 3 | AVDL |
AVADEL PHARMACEUTICALS PLC
ADSs |
6.205.346 | ||||||||
2018-12-13 | 3 | AVDL |
AVADEL PHARMACEUTICALS PLC
ADSs |
6.205.346 | ||||||||
2018-11-28 |
|
4 | CORI |
Corium International, Inc.
Common Stock |
U - Other | -4.474.995 | 0 | -100,00 | ||||
2018-10-15 | 3 | CORI |
Corium International, Inc.
Common Stock |
8.949.990 | ||||||||
2018-10-15 | 3 | CORI |
Corium International, Inc.
Common Stock |
8.949.990 | ||||||||
2018-10-15 | 3 | CORI |
Corium International, Inc.
Common Stock |
8.949.990 | ||||||||
2018-10-15 | 3 | CORI |
Corium International, Inc.
Common Stock |
8.949.990 | ||||||||
2018-10-15 | 3 | CORI |
Corium International, Inc.
Common Stock |
8.949.990 | ||||||||
2018-08-16 |
|
4 | BDSI |
BIODELIVERY SCIENCES INTERNATIONAL INC
Restricted Stock Units |
M - Exercise | 3.124 | 93.123 | 3,47 | ||||
2018-08-16 |
|
4 | BDSI |
BIODELIVERY SCIENCES INTERNATIONAL INC
Common Stock |
M - Exercise | 3.124 | 3.124 | |||||
2018-08-13 |
|
4 | NVLN |
NOVELION THERAPEUTICS INC.
Stock Option (Right to Buy) |
G - Gift | 10.000 | 19.600 | 104,17 | ||||
2018-08-13 |
|
4 | NVLN |
NOVELION THERAPEUTICS INC.
Stock Option (Right to Buy) |
G - Gift | -10.000 | 19.600 | -33,78 | ||||
2018-08-03 |
|
4 | BDSI |
BIODELIVERY SCIENCES INTERNATIONAL INC
Stock Options (right to buy) |
A - Award | 48.123 | 48.123 | |||||
2018-08-03 |
|
4 | BDSI |
BIODELIVERY SCIENCES INTERNATIONAL INC
Restricted Stock Units |
A - Award | 96.247 | 96.247 | |||||
2018-05-24 |
|
4 | REPH |
Recro Pharma, Inc.
Common Stock, $0.01 par value per share |
S - Sale | -25.000 | 2.048.025 | -1,21 | 5,51 | -137.750 | 11.284.618 | |
2018-05-24 |
|
4 | REPH |
Recro Pharma, Inc.
Common Stock, $0.01 par value per share |
S - Sale | -50.000 | 2.073.025 | -2,36 | 5,65 | -282.500 | 11.712.591 | |
2018-05-24 |
|
4 | REPH |
Recro Pharma, Inc.
Common Stock, $0.01 par value per share |
S - Sale | -45.700 | 2.123.025 | -2,11 | 6,00 | -274.200 | 12.738.150 | |
2018-05-24 |
|
4 | REPH |
Recro Pharma, Inc.
Common Stock, $0.01 par value per share |
S - Sale | -38.000 | 2.168.725 | -1,72 | 5,99 | -227.620 | 12.990.663 | |
2018-05-24 |
|
4 | REPH |
Recro Pharma, Inc.
Common Stock, $0.01 par value per share |
S - Sale | -29.300 | 2.206.725 | -1,31 | 5,84 | -171.112 | 12.887.274 | |
2018-05-23 | 3 | BDSI |
BIODELIVERY SCIENCES INTERNATIONAL INC
Common Stock |
8.557.638 | ||||||||
2018-05-23 | 3 | BDSI |
BIODELIVERY SCIENCES INTERNATIONAL INC
Common Stock |
8.557.638 | ||||||||
2018-05-23 | 3 | BDSI |
BIODELIVERY SCIENCES INTERNATIONAL INC
Common Stock |
8.557.638 | ||||||||
2018-05-23 | 3 | BDSI |
BIODELIVERY SCIENCES INTERNATIONAL INC
Common Stock |
8.557.638 | ||||||||
2018-03-19 |
|
4 | NVLN |
NOVELION THERAPEUTICS INC.
Warrants |
A - Award | 909.296 | 909.296 | |||||
2018-03-15 |
|
4 | REPH |
Recro Pharma, Inc.
Common Stock, $0.01 par value per share |
S - Sale | -200.000 | 2.236.025 | -8,21 | 10,07 | -2.014.000 | 22.516.772 | |
2017-12-22 |
|
4 | REPH |
Recro Pharma, Inc.
Common Stock, $0.01 par value per share |
S - Sale | -40.000 | 2.436.025 | -1,62 | 9,80 | -392.000 | 23.873.045 | |
2017-12-22 |
|
4 | REPH |
Recro Pharma, Inc.
Common Stock, $0.01 par value per share |
S - Sale | -11.000 | 2.476.025 | -0,44 | 9,84 | -108.240 | 24.364.086 | |
2017-12-22 |
|
4 | REPH |
Recro Pharma, Inc.
Common Stock, $0.01 par value per share |
S - Sale | -25.000 | 2.487.025 | -1,00 | 10,00 | -250.000 | 24.870.250 | |
2017-12-14 |
|
4 | REPH |
Recro Pharma, Inc.
Common Stock, $0.01 par value per share |
S - Sale | -8.237 | 2.512.025 | -0,33 | 9,80 | -80.723 | 24.617.845 | |
2017-12-14 |
|
4 | REPH |
Recro Pharma, Inc.
Common Stock, $0.01 par value per share |
S - Sale | -9.900 | 2.520.262 | -0,39 | 9,84 | -97.416 | 24.799.378 | |
2017-12-14 |
|
4 | REPH |
Recro Pharma, Inc.
Common Stock, $0.01 par value per share |
S - Sale | -50.000 | 2.530.162 | -1,94 | 9,80 | -490.000 | 24.795.588 | |
2017-12-14 |
|
4 | REPH |
Recro Pharma, Inc.
Common Stock, $0.01 par value per share |
S - Sale | -100 | 2.580.162 | 0,00 | 9,89 | -989 | 25.517.802 | |
2017-12-14 |
|
4 | REPH |
Recro Pharma, Inc.
Common Stock, $0.01 par value per share |
S - Sale | -25.000 | 2.580.262 | -0,96 | 10,00 | -250.000 | 25.802.620 | |
2017-12-07 |
|
4 | REPH |
Recro Pharma, Inc.
Common Stock, $0.01 par value per share |
S - Sale | -100.000 | 2.605.262 | -3,70 | 10,00 | -1.000.000 | 26.052.620 | |
2017-12-01 |
|
4 | PETX |
ARATANA THERAPEUTICS, INC.
Common Stock |
S - Sale | -425.298 | 4.294.426 | -9,01 | 5,40 | -2.296.609 | 23.189.900 | |
2017-12-01 |
|
4 | PETX |
ARATANA THERAPEUTICS, INC.
Common Stock |
S - Sale | -1.900 | 4.719.724 | -0,04 | 5,44 | -10.336 | 25.675.299 | |
2017-12-01 |
|
4 | PETX |
ARATANA THERAPEUTICS, INC.
Common Stock |
S - Sale | -50.000 | 4.721.624 | -1,05 | 5,45 | -272.500 | 25.732.851 | |
2017-12-01 |
|
4 | PETX |
ARATANA THERAPEUTICS, INC.
Common Stock |
S - Sale | -100 | 4.771.624 | 0,00 | 5,47 | -547 | 26.100.783 | |
2017-12-01 |
|
4 | PETX |
ARATANA THERAPEUTICS, INC.
Common Stock |
S - Sale | -5.110 | 4.771.724 | -0,11 | 5,52 | -28.207 | 26.339.916 | |
2017-12-01 |
|
4 | PETX |
ARATANA THERAPEUTICS, INC.
Common Stock |
S - Sale | -8.020 | 4.776.834 | -0,17 | 5,53 | -44.351 | 26.415.892 | |
2017-12-01 |
|
4 | PETX |
ARATANA THERAPEUTICS, INC.
Common Stock |
S - Sale | -72.000 | 4.784.854 | -1,48 | 5,65 | -406.800 | 27.034.425 | |
2017-12-01 |
|
4 | PETX |
ARATANA THERAPEUTICS, INC.
Common Stock |
S - Sale | -50.000 | 4.856.854 | -1,02 | 5,90 | -295.000 | 28.655.439 | |
2017-12-01 |
|
4 | PETX |
ARATANA THERAPEUTICS, INC.
Common Stock |
S - Sale | -50.000 | 4.906.854 | -1,01 | 5,95 | -297.500 | 29.195.781 | |
2017-12-01 |
|
4 | PETX |
ARATANA THERAPEUTICS, INC.
Common Stock |
S - Sale | -100.000 | 4.956.854 | -1,98 | 5,95 | -595.000 | 29.493.281 | |
2017-12-01 |
|
4 | PETX |
ARATANA THERAPEUTICS, INC.
Common Stock |
S - Sale | -11.472 | 5.056.854 | -0,23 | 5,97 | -68.488 | 30.189.418 | |
2017-12-01 |
|
4 | PETX |
ARATANA THERAPEUTICS, INC.
Common Stock |
S - Sale | -100 | 5.068.326 | 0,00 | 6,03 | -603 | 30.562.006 | |
2017-12-01 |
|
4 | PETX |
ARATANA THERAPEUTICS, INC.
Common Stock |
S - Sale | -1.900 | 5.068.426 | -0,04 | 6,26 | -11.894 | 31.728.347 | |
2017-12-01 |
|
4 | PETX |
ARATANA THERAPEUTICS, INC.
Common Stock |
S - Sale | -300 | 5.070.326 | -0,01 | 6,28 | -1.884 | 31.841.647 | |
2017-12-01 |
|
4 | PETX |
ARATANA THERAPEUTICS, INC.
Common Stock |
S - Sale | -7.700 | 5.070.626 | -0,15 | 6,35 | -48.895 | 32.198.475 | |
2017-12-01 |
|
4 | PETX |
ARATANA THERAPEUTICS, INC.
Common Stock |
S - Sale | -50.000 | 5.078.326 | -0,97 | 6,50 | -325.000 | 33.009.119 | |
2017-12-01 |
|
4 | PETX |
ARATANA THERAPEUTICS, INC.
Common Stock |
S - Sale | -5.751 | 5.128.326 | -0,11 | 6,55 | -37.669 | 33.590.535 | |
2017-12-01 |
|
4 | PETX |
ARATANA THERAPEUTICS, INC.
Common Stock |
S - Sale | -49.865 | 5.134.077 | -0,96 | 6,60 | -329.109 | 33.884.908 | |
2017-12-01 |
|
4 | PETX |
ARATANA THERAPEUTICS, INC.
Common Stock |
S - Sale | -1.000 | 5.183.942 | -0,02 | 6,66 | -6.660 | 34.525.054 | |
2017-11-30 |
|
4 | REPH |
Recro Pharma, Inc.
Common Stock, $0.01 par value per share |
S - Sale | -100 | 2.705.262 | 0,00 | 9,61 | -961 | 25.997.568 | |
2017-11-30 |
|
4 | REPH |
Recro Pharma, Inc.
Common Stock, $0.01 par value per share |
S - Sale | -100.000 | 2.705.362 | -3,56 | 9,55 | -955.000 | 25.836.207 | |
2017-11-30 |
|
4 | REPH |
Recro Pharma, Inc.
Common Stock, $0.01 par value per share |
S - Sale | -50.000 | 2.805.362 | -1,75 | 9,55 | -477.500 | 26.791.207 | |
2017-11-30 |
|
4 | REPH |
Recro Pharma, Inc.
Common Stock, $0.01 par value per share |
S - Sale | -5.000 | 2.855.362 | -0,17 | 9,62 | -48.100 | 27.468.582 | |
2017-11-30 |
|
4 | REPH |
Recro Pharma, Inc.
Common Stock, $0.01 par value per share |
S - Sale | -500 | 2.860.362 | -0,02 | 9,69 | -4.845 | 27.716.908 | |
2017-11-30 |
|
4 | REPH |
Recro Pharma, Inc.
Common Stock, $0.01 par value per share |
S - Sale | -6.322 | 2.860.862 | -0,22 | 9,63 | -60.881 | 27.550.101 | |
2017-11-30 |
|
4 | REPH |
Recro Pharma, Inc.
Common Stock, $0.01 par value per share |
S - Sale | -100 | 2.867.184 | 0,00 | 9,71 | -971 | 27.840.357 | |
2017-11-30 |
|
4 | REPH |
Recro Pharma, Inc.
Common Stock, $0.01 par value per share |
S - Sale | -6.381 | 2.867.284 | -0,22 | 9,71 | -61.960 | 27.841.328 | |
2017-11-30 |
|
4 | REPH |
Recro Pharma, Inc.
Common Stock, $0.01 par value per share |
S - Sale | -3.764 | 2.873.665 | -0,13 | 9,66 | -36.360 | 27.759.604 | |
2017-11-30 |
|
4 | REPH |
Recro Pharma, Inc.
Common Stock, $0.01 par value per share |
S - Sale | -700 | 2.877.429 | -0,02 | 9,68 | -6.776 | 27.853.513 | |
2017-11-30 |
|
4 | REPH |
Recro Pharma, Inc.
Common Stock, $0.01 par value per share |
S - Sale | -2.200 | 2.878.129 | -0,08 | 9,68 | -21.296 | 27.860.289 | |
2017-11-30 |
|
4 | REPH |
Recro Pharma, Inc.
Common Stock, $0.01 par value per share |
S - Sale | -21.619 | 2.880.329 | -0,74 | 9,56 | -206.678 | 27.535.945 | |
2017-11-30 |
|
4 | REPH |
Recro Pharma, Inc.
Common Stock, $0.01 par value per share |
S - Sale | -1.500 | 2.901.948 | -0,05 | 9,68 | -14.520 | 28.090.857 | |
2017-11-30 |
|
4 | REPH |
Recro Pharma, Inc.
Common Stock, $0.01 par value per share |
S - Sale | -24.430 | 2.903.448 | -0,83 | 9,71 | -237.215 | 28.192.480 | |
2017-11-24 |
|
4 | REPH |
Recro Pharma, Inc.
Common Stock, $0.01 par value per share |
S - Sale | -5.900 | 2.927.878 | -0,20 | 9,37 | -55.283 | 27.434.217 | |
2017-11-24 |
|
4 | REPH |
Recro Pharma, Inc.
Common Stock, $0.01 par value per share |
S - Sale | -1.450 | 2.933.778 | -0,05 | 9,48 | -13.746 | 27.812.215 | |
2017-11-24 |
|
4 | REPH |
Recro Pharma, Inc.
Common Stock, $0.01 par value per share |
S - Sale | -5.800 | 2.935.228 | -0,20 | 9,39 | -54.462 | 27.561.791 | |
2017-11-24 |
|
4 | REPH |
Recro Pharma, Inc.
Common Stock, $0.01 par value per share |
S - Sale | -2.051 | 2.941.028 | -0,07 | 9,31 | -19.095 | 27.380.971 | |
2017-11-24 |
|
4 | REPH |
Recro Pharma, Inc.
Common Stock, $0.01 par value per share |
S - Sale | -2.913 | 2.943.079 | -0,10 | 9,32 | -27.149 | 27.429.496 | |
2017-11-24 |
|
4 | REPH |
Recro Pharma, Inc.
Common Stock, $0.01 par value per share |
S - Sale | -3.088 | 2.945.992 | -0,10 | 9,36 | -28.904 | 27.574.485 | |
2017-11-24 |
|
4 | REPH |
Recro Pharma, Inc.
Common Stock, $0.01 par value per share |
S - Sale | -48.566 | 2.949.080 | -1,62 | 9,37 | -455.063 | 27.632.880 | |
2017-11-24 |
|
4 | REPH |
Recro Pharma, Inc.
Common Stock, $0.01 par value per share |
S - Sale | -2.440 | 2.997.646 | -0,08 | 9,37 | -22.863 | 28.087.943 | |
2017-11-24 |
|
4 | REPH |
Recro Pharma, Inc.
Common Stock, $0.01 par value per share |
S - Sale | -100.000 | 3.000.086 | -3,23 | 9,50 | -950.000 | 28.500.817 | |
2017-11-20 |
|
4 | MRTX |
Mirati Therapeutics, Inc.
Common Stock |
S - Sale | -60.000 | 2.728.601 | -2,15 | 18,05 | -1.083.000 | 49.251.248 | |
2017-11-20 | 3 | MRTX |
Mirati Therapeutics, Inc.
Common Stock |
5.577.202 | ||||||||
2017-11-20 | 3 | MRTX |
Mirati Therapeutics, Inc.
Common Stock |
5.577.202 | ||||||||
2017-11-20 | 3 | MRTX |
Mirati Therapeutics, Inc.
Common Stock |
5.577.202 | ||||||||
2017-11-20 | 3 | MRTX |
Mirati Therapeutics, Inc.
Common Stock |
5.577.202 | ||||||||
2017-11-17 |
|
4 | CORI |
Corium International, Inc.
Common Stock |
S - Sale | -25.000 | 3.568.626 | -0,70 | 10,95 | -273.750 | 39.076.455 | |
2017-11-17 |
|
4 | CORI |
Corium International, Inc.
Common Stock |
S - Sale | -9.255 | 3.593.626 | -0,26 | 10,96 | -101.435 | 39.386.141 | |
2017-11-17 |
|
4 | CORI |
Corium International, Inc.
Common Stock |
S - Sale | -100.000 | 3.602.881 | -2,70 | 10,95 | -1.095.000 | 39.451.547 | |
2017-11-17 |
|
4 | CORI |
Corium International, Inc.
Common Stock |
S - Sale | -65.345 | 3.702.881 | -1,73 | 11,01 | -719.448 | 40.768.720 | |
2017-11-17 |
|
4 | CORI |
Corium International, Inc.
Common Stock |
S - Sale | -400 | 3.768.226 | -0,01 | 10,97 | -4.388 | 41.337.439 | |
2017-11-17 |
|
4 | CORI |
Corium International, Inc.
Common Stock |
S - Sale | -25.000 | 3.768.626 | -0,66 | 10,88 | -272.000 | 41.002.651 | |
2017-11-17 |
|
4 | CORI |
Corium International, Inc.
Common Stock |
S - Sale | -25.000 | 3.793.626 | -0,65 | 10,85 | -271.250 | 41.160.842 | |
2017-11-17 |
|
4 | CORI |
Corium International, Inc.
Common Stock |
S - Sale | -250.000 | 3.818.626 | -6,14 | 10,97 | -2.742.500 | 41.890.327 | |
2017-11-03 |
|
4 | CORI |
Corium International, Inc.
Common Stock |
S - Sale | -150.000 | 4.068.626 | -3,56 | 11,05 | -1.657.500 | 44.958.317 | |
2017-10-06 |
|
4 | CORI |
Corium International, Inc.
Common Stock |
S - Sale | -218.100 | 4.218.626 | -4,92 | 11,01 | -2.401.107 | 46.443.697 | |
2017-06-26 |
|
4 | AVDL |
AVADEL PHARMACEUTICALS PLC
Ordinary Shares |
S - Sale | -161.000 | 4.133.464 | -3,75 | 10,60 | -1.706.600 | 43.814.718 | |
2017-06-26 |
|
4 | AVDL |
AVADEL PHARMACEUTICALS PLC
Ordinary Shares |
S - Sale | -100.000 | 4.294.464 | -2,28 | 10,80 | -1.080.000 | 46.380.211 | |
2017-05-25 | 3 | CORI |
Corium International, Inc.
Common Stock |
8.873.452 | ||||||||
2017-05-25 | 3 | CORI |
Corium International, Inc.
Common Stock |
8.873.452 | ||||||||
2017-05-25 | 3 | CORI |
Corium International, Inc.
Common Stock |
8.873.452 | ||||||||
2017-05-25 | 3 | CORI |
Corium International, Inc.
Common Stock |
8.873.452 | ||||||||
2017-05-22 |
|
4 | PETX |
ARATANA THERAPEUTICS, INC.
Put Option (obligation to buy) |
X - Other | -7.295 | 0 | -100,00 | ||||
2017-05-22 |
|
4 | PETX |
ARATANA THERAPEUTICS, INC.
Common Stock |
X - Other | 729.500 | 5.184.942 | 16,37 | 7,50 | 5.471.250 | 38.887.065 | |
2017-05-11 | 3 | PETX |
ARATANA THERAPEUTICS, INC.
Common Stock |
8.910.884 | ||||||||
2017-05-11 | 3 | PETX |
ARATANA THERAPEUTICS, INC.
Common Stock |
8.910.884 | ||||||||
2017-05-11 | 3 | PETX |
ARATANA THERAPEUTICS, INC.
Common Stock |
8.910.884 | ||||||||
2017-05-11 | 3 | PETX |
ARATANA THERAPEUTICS, INC.
Common Stock |
8.910.884 | ||||||||
2017-02-15 |
|
4 | PGNX |
PROGENICS PHARMACEUTICALS INC
Common Stock |
S - Sale | -150.000 | 6.997.269 | -2,10 | 9,55 | -1.432.500 | 66.823.919 | |
2017-02-15 |
|
4 | PGNX |
PROGENICS PHARMACEUTICALS INC
Common Stock |
S - Sale | -150.000 | 7.147.269 | -2,06 | 9,68 | -1.452.000 | 69.185.564 | |
2017-02-15 |
|
4 | PGNX |
PROGENICS PHARMACEUTICALS INC
Common Stock |
S - Sale | -100.000 | 7.297.269 | -1,35 | 9,70 | -970.000 | 70.783.509 | |
2017-02-15 |
|
4 | PGNX |
PROGENICS PHARMACEUTICALS INC
Common Stock |
S - Sale | -50.000 | 7.397.269 | -0,67 | 9,70 | -485.000 | 71.753.509 | |
2017-02-15 |
|
4 | PGNX |
PROGENICS PHARMACEUTICALS INC
Common Stock |
S - Sale | -52.600 | 7.447.269 | -0,70 | 9,70 | -510.220 | 72.238.509 | |
2017-02-15 |
|
4 | PGNX |
PROGENICS PHARMACEUTICALS INC
Common Stock |
S - Sale | -100.000 | 7.499.869 | -1,32 | 9,70 | -970.000 | 72.748.729 | |
2017-02-09 |
|
4 | PGNX |
PROGENICS PHARMACEUTICALS INC
Common Stock |
S - Sale | -1.300 | 7.599.869 | -0,02 | 9,68 | -12.590 | 73.604.731 | |
2017-02-09 |
|
4 | PGNX |
PROGENICS PHARMACEUTICALS INC
Common Stock |
S - Sale | -100.000 | 7.601.169 | -1,30 | 9,66 | -966.000 | 73.427.293 | |
2017-02-09 |
|
4 | PGNX |
PROGENICS PHARMACEUTICALS INC
Common Stock |
S - Sale | -100.000 | 7.701.169 | -1,28 | 9,75 | -975.000 | 75.086.398 | |
2017-02-09 |
|
4 | PGNX |
PROGENICS PHARMACEUTICALS INC
Common Stock |
S - Sale | -50.000 | 7.801.169 | -0,64 | 9,65 | -482.500 | 75.281.281 | |
2017-02-09 |
|
4 | PGNX |
PROGENICS PHARMACEUTICALS INC
Common Stock |
S - Sale | -100.000 | 7.851.169 | -1,26 | 9,74 | -974.000 | 76.470.386 | |
2017-01-13 |
|
4 | PGNX |
PROGENICS PHARMACEUTICALS INC
Common Stock |
D - Sale to Issuer | -1.000.000 | 7.951.169 | -11,17 | 8,95 | -8.950.000 | 71.162.963 | |
2017-01-06 |
|
4 | AVDL |
AVADEL PHARMACEUTICALS PLC
Ordinary Shares |
D - Sale to Issuer | -4.394.464 | 0 | -100,00 | ||||
2017-01-06 | 3 | AVDL |
AVADEL PHARMACEUTICALS PLC
Ordinary Shares |
8.788.928 | ||||||||
2017-01-06 | 3 | AVDL |
AVADEL PHARMACEUTICALS PLC
Ordinary Shares |
8.788.928 | ||||||||
2017-01-06 | 3 | AVDL |
AVADEL PHARMACEUTICALS PLC
Ordinary Shares |
8.788.928 | ||||||||
2017-01-06 | 3 | AVDL |
AVADEL PHARMACEUTICALS PLC
Ordinary Shares |
8.788.928 | ||||||||
2017-01-06 | 3 | AVDL |
AVADEL PHARMACEUTICALS PLC
Ordinary Shares |
8.788.928 | ||||||||
2017-01-06 | 3 | AVDL |
AVADEL PHARMACEUTICALS PLC
Ordinary Shares |
8.788.928 | ||||||||
2017-01-06 | 3 | AVDL |
AVADEL PHARMACEUTICALS PLC
Ordinary Shares |
8.788.928 | ||||||||
2017-01-06 | 3 | AVDL |
AVADEL PHARMACEUTICALS PLC
Ordinary Shares |
8.788.928 | ||||||||
2016-12-27 |
|
4 | NVLN |
NOVELION THERAPEUTICS INC.
Stock Option (Right to Buy) |
A - Award | 9.600 | 9.600 | |||||
2016-12-27 |
|
4 | NVLN |
NOVELION THERAPEUTICS INC.
Stock Option (Right to Buy) |
G - Gift | 9.600 | 9.600 | |||||
2016-12-27 |
|
4 | NVLN |
NOVELION THERAPEUTICS INC.
Stock Option (Right to Buy) |
G - Gift | -9.600 | 9.600 | -50,00 | ||||
2016-12-14 |
|
4 | REPH |
Recro Pharma, Inc.
Common Stock, $0.01 par value per share |
P - Purchase | 650.000 | 3.100.086 | 26,53 | 6,00 | 3.900.000 | 18.600.516 | |
2016-12-01 |
|
4 | NVLN |
QLT INC/BC
Warrants for Common Shares (Right to Buy) |
A - Award | 2.840.909 | 2.840.909 | |||||
2016-12-01 |
|
4 | NVLN |
QLT INC/BC
Common Shares, without par value |
A - Award | 4.472.940 | 9.742.771 | 84,88 | ||||
2016-12-01 |
|
4 | AEGR |
Aegerion Pharmaceuticals, Inc.
Common Stock, $0.001 par value |
D - Sale to Issuer | -4.361.291 | 0 | -100,00 | ||||
2016-12-01 | 3 | NVLN |
QLT INC/BC
Common Shares, without par value |
10.539.662 | ||||||||
2016-12-01 | 3 | NVLN |
QLT INC/BC
Common Shares, without par value |
10.539.662 | ||||||||
2016-12-01 | 3 | NVLN |
QLT INC/BC
Common Shares, without par value |
10.539.662 | ||||||||
2016-12-01 | 3 | NVLN |
QLT INC/BC
Common Shares, without par value |
10.539.662 | ||||||||
2016-09-14 |
|
4 | AEGR |
Aegerion Pharmaceuticals, Inc.
Common Stock, $0.001 par value |
P - Purchase | 75.000 | 4.361.291 | 1,75 | 1,75 | 131.250 | 7.632.259 | |
2016-09-12 |
|
4 | AEGR |
Aegerion Pharmaceuticals, Inc.
Common Stock, $0.001 par value |
P - Purchase | 76.000 | 4.286.291 | 1,81 | 1,70 | 129.200 | 7.286.695 | |
2016-09-12 |
|
4 | AEGR |
Aegerion Pharmaceuticals, Inc.
Common Stock, $0.001 par value |
P - Purchase | 100.000 | 4.210.291 | 2,43 | 1,70 | 169.600 | 7.140.654 | |
2016-09-12 |
|
4 | AEGR |
Aegerion Pharmaceuticals, Inc.
Common Stock, $0.001 par value |
P - Purchase | 100.000 | 4.110.291 | 2,49 | 1,60 | 159.500 | 6.555.914 | |
2016-08-17 |
|
4 | REPH |
Recro Pharma, Inc.
Common Shares |
P - Purchase | 390.000 | 2.450.086 | 18,93 | 7,50 | 2.925.000 | 18.375.645 | |
2016-03-21 |
|
4 | AEGR |
Aegerion Pharmaceuticals, Inc.
Put Options (obligation to buy) |
X - Other | -4.976 | 0 | -100,00 | ||||
2016-03-21 |
|
4 | AEGR |
Aegerion Pharmaceuticals, Inc.
Call Options (obligation to sell) |
E - Other | -5.000 | 0 | -100,00 | ||||
2016-03-21 |
|
4 | AEGR |
Aegerion Pharmaceuticals, Inc.
Common Stock, $0.001 par value |
X - Other | 497.600 | 4.010.291 | 14,17 | 7,50 | 3.732.000 | 30.077.182 | |
2016-03-21 |
|
4 | AEGR |
Aegerion Pharmaceuticals, Inc.
Put Options (obligation to buy) |
X - Other | -24 | 0 | -100,00 | ||||
2016-03-21 |
|
4 | AEGR |
Aegerion Pharmaceuticals, Inc.
Common Stock, $0.001 par value |
X - Other | 2.400 | 3.512.691 | 0,07 | 7,50 | 18.000 | 26.345.182 | |
2016-03-14 |
|
4 | SSKN |
STRATA Skin Sciences, Inc.
Common Stock |
S - Sale | -200.000 | 1.008.297 | -16,55 | 1,28 | -256.000 | 1.290.620 | |
2016-03-14 |
|
4 | SSKN |
STRATA Skin Sciences, Inc.
Common Stock |
S - Sale | -16.000 | 1.208.297 | -1,31 | 1,05 | -16.800 | 1.268.712 | |
2016-03-14 |
|
4 | SSKN |
STRATA Skin Sciences, Inc.
Common Stock |
S - Sale | -25.000 | 1.224.297 | -2,00 | 1,50 | -37.500 | 1.836.446 | |
2016-03-14 |
|
4 | SSKN |
STRATA Skin Sciences, Inc.
Common Stock |
S - Sale | -23.500 | 1.249.297 | -1,85 | 1,50 | -35.250 | 1.873.946 | |
2016-03-14 |
|
4 | SSKN |
STRATA Skin Sciences, Inc.
Common Stock |
S - Sale | -1.500 | 1.272.797 | -0,12 | 1,51 | -2.265 | 1.921.923 | |
2015-11-13 |
|
4 | AEGR |
Aegerion Pharmaceuticals, Inc.
Common Stock, $0.001 par value |
P - Purchase | 35.000 | 4.010.291 | 0,88 | 10,96 | 383.600 | 43.952.789 | |
2015-11-13 |
|
4 | AEGR |
Aegerion Pharmaceuticals, Inc.
Common Stock, $0.001 par value |
P - Purchase | 5.100 | 3.975.291 | 0,13 | 10,99 | 56.049 | 43.688.448 | |
2015-11-13 | 3 | AEGR |
Aegerion Pharmaceuticals, Inc.
Common Stock, $0.001 par value |
6.940.382 | ||||||||
2015-11-13 | 3 | AEGR |
Aegerion Pharmaceuticals, Inc.
Common Stock, $0.001 par value |
6.940.382 | ||||||||
2015-11-13 | 3 | AEGR |
Aegerion Pharmaceuticals, Inc.
Common Stock, $0.001 par value |
6.940.382 | ||||||||
2015-11-13 | 3 | AEGR |
Aegerion Pharmaceuticals, Inc.
Common Stock, $0.001 par value |
6.940.382 | ||||||||
2015-09-14 | 3 | CRDC |
CARDICA INC
Common Stock |
17.749.984 | ||||||||
2015-09-14 | 3 | CRDC |
CARDICA INC
Common Stock |
17.749.984 | ||||||||
2015-09-14 | 3 | CRDC |
CARDICA INC
Common Stock |
17.749.984 | ||||||||
2015-09-14 | 3 | CRDC |
CARDICA INC
Common Stock |
17.749.984 | ||||||||
2015-09-14 | 3 | CRDC |
CARDICA INC
Common Stock |
17.749.984 | ||||||||
2015-09-14 | 3 | CRDC |
CARDICA INC
Common Stock |
17.749.984 | ||||||||
2015-09-14 | 3 | CRDC |
CARDICA INC
Common Stock |
17.749.984 | ||||||||
2015-08-24 | 3 | MELA |
MELA SCIENCES, INC. /NY
Common Stock |
3.822.891 | ||||||||
2015-08-24 | 3 | MELA |
MELA SCIENCES, INC. /NY
Common Stock |
3.822.891 | ||||||||
2015-08-24 | 3 | MELA |
MELA SCIENCES, INC. /NY
Common Stock |
3.822.891 | ||||||||
2015-08-24 | 3 | MELA |
MELA SCIENCES, INC. /NY
Common Stock |
3.822.891 | ||||||||
2015-08-24 | 3 | MELA |
MELA SCIENCES, INC. /NY
Common Stock |
3.822.891 | ||||||||
2015-08-24 | 3 | MELA |
MELA SCIENCES, INC. /NY
Common Stock |
3.822.891 | ||||||||
2015-08-24 | 3 | MELA |
MELA SCIENCES, INC. /NY
Common Stock |
3.822.891 | ||||||||
2015-08-24 | 3 | MELA |
MELA SCIENCES, INC. /NY
Common Stock |
3.822.891 | ||||||||
2015-07-09 |
|
4 | REPH |
Recro Pharma, Inc.
Common Shares |
P - Purchase | 646.553 | 2.060.086 | 45,74 | 11,60 | 7.500.015 | 23.896.998 | |
2015-01-30 | 3 | RTRX |
Retrophin, Inc.
Common Stock |
5.317.708 | ||||||||
2015-01-30 | 3 | RTRX |
Retrophin, Inc.
Common Stock |
5.317.708 | ||||||||
2015-01-30 | 3 | RTRX |
Retrophin, Inc.
Common Stock |
5.317.708 | ||||||||
2015-01-30 | 3 | RTRX |
Retrophin, Inc.
Common Stock |
5.317.708 | ||||||||
2014-12-04 |
|
4 | REPH |
Recro Pharma, Inc.
Common Stock |
P - Purchase | 241.338 | 1.413.533 | 20,59 | 2,50 | 603.345 | 3.533.832 | |
2014-09-18 | 3 | REPH |
Recro Pharma, Inc.
Common Stock |
2.344.390 | ||||||||
2014-09-18 | 3 | REPH |
Recro Pharma, Inc.
Common Stock |
2.344.390 | ||||||||
2014-09-18 | 3 | REPH |
Recro Pharma, Inc.
Common Stock |
2.344.390 | ||||||||
2014-09-18 | 3 | REPH |
Recro Pharma, Inc.
Common Stock |
2.344.390 | ||||||||
2014-07-23 |
|
4 | PGNX |
PROGENICS PHARMACEUTICALS INC
Common Stock |
P - Purchase | 388.659 | 8.951.169 | 4,54 | 4,73 | 1.838.357 | 42.339.029 | |
2014-07-23 |
|
4 | PGNX |
PROGENICS PHARMACEUTICALS INC
Common Stock |
P - Purchase | 388.200 | 8.562.510 | 4,75 | 4,73 | 1.836.186 | 40.500.672 | |
2014-07-23 |
|
4 | PGNX |
PROGENICS PHARMACEUTICALS INC
Common Stock |
P - Purchase | 436.884 | 8.174.310 | 5,65 | 4,48 | 1.957.240 | 36.620.909 | |
2014-07-23 |
|
4 | PGNX |
PROGENICS PHARMACEUTICALS INC
Common Stock |
P - Purchase | 411.693 | 7.737.426 | 5,62 | 4,48 | 1.844.385 | 34.663.668 | |
2014-07-23 | 3 | PGNX |
PROGENICS PHARMACEUTICALS INC
Common Stock |
14.651.466 | ||||||||
2014-07-23 | 3 | PGNX |
PROGENICS PHARMACEUTICALS INC
Common Stock |
14.651.466 | ||||||||
2014-07-23 | 3 | PGNX |
PROGENICS PHARMACEUTICALS INC
Common Stock |
14.651.466 | ||||||||
2014-07-23 | 3 | PGNX |
PROGENICS PHARMACEUTICALS INC
Common Stock |
14.651.466 |